CRVO
CervoMed Inc.Healthcare · $24M market cap
Verdict
We can't put a fair value on CRVO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow CRVO
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 22, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about CRVO
Are insiders buying CRVO?
Since Oct 22, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar).
How can I check CRVO's value myself?
Use the free Sticker Price calculator, already filled with CRVO's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 23, 2026. How the Payback Price works